CN113840836A - 抗***生长因子抗体及其应用 - Google Patents

抗***生长因子抗体及其应用 Download PDF

Info

Publication number
CN113840836A
CN113840836A CN202080036744.2A CN202080036744A CN113840836A CN 113840836 A CN113840836 A CN 113840836A CN 202080036744 A CN202080036744 A CN 202080036744A CN 113840836 A CN113840836 A CN 113840836A
Authority
CN
China
Prior art keywords
seq
variable region
chain variable
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080036744.2A
Other languages
English (en)
Other versions
CN113840836B (zh
Inventor
付雅媛
马晓丽
葛虎
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN202211129173.4A priority Critical patent/CN115925926A/zh
Publication of CN113840836A publication Critical patent/CN113840836A/zh
Application granted granted Critical
Publication of CN113840836B publication Critical patent/CN113840836B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Abstract

提供一种包含轻链和重链可变区的抗CTGF抗体及其作为药物的用途，该抗体可用于制备治疗CTGF相关疾病或病症的药物。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080036744.2A 2019-06-04 2020-06-03 抗***生长因子抗体及其应用 Active CN113840836B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211129173.4A CN115925926A (zh) 2019-06-04 2020-06-03 抗***生长因子抗体及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910480169 2019-06-04
CN2019104801694 2019-06-04
PCT/CN2020/094136 WO2020244540A1 (zh) 2019-06-04 2020-06-03 抗***生长因子抗体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211129173.4A Division CN115925926A (zh) 2019-06-04 2020-06-03 抗***生长因子抗体及其应用

Publications (2)

Publication Number Publication Date
CN113840836A true CN113840836A (zh) 2021-12-24
CN113840836B CN113840836B (zh) 2022-10-21

Family

ID=73653057

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211129173.4A Pending CN115925926A (zh) 2019-06-04 2020-06-03 抗***生长因子抗体及其应用
CN202080036744.2A Active CN113840836B (zh) 2019-06-04 2020-06-03 抗***生长因子抗体及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211129173.4A Pending CN115925926A (zh) 2019-06-04 2020-06-03 抗***生长因子抗体及其应用

Country Status (12)

Country Link
US (1) US20220324953A1 (zh)
EP (1) EP3981787A4 (zh)
JP (1) JP2022535810A (zh)
KR (1) KR20220016890A (zh)
CN (2) CN115925926A (zh)
AU (1) AU2020289303A1 (zh)
BR (1) BR112021023669A2 (zh)
CA (1) CA3142092A1 (zh)
MX (1) MX2021014803A (zh)
TW (1) TW202110880A (zh)
WO (1) WO2020244540A1 (zh)
ZA (1) ZA202109744B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645525A (zh) * 2022-12-14 2023-01-31 北京大学第三医院（北京大学第三临床医学院） Ctgf中和抗体在制备防治绝经后骨关节炎的药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116391041A (zh) * 2020-12-03 2023-07-04 江苏恒瑞医药股份有限公司 一种含抗***生长因子抗体的药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011206A (zh) * 2011-12-22 2014-08-27 安斯泰来制药株式会社 新型抗人ctgf抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
WO1999033878A1 (fr) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
JP4863548B2 (ja) 1998-09-08 2012-01-25 ヘンリー フォード ヘルス システム 結合組織増殖因子のモジュレーション、調節および抑制による腎障害の検出、予防および治療方法
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
CN101884789A (zh) * 2004-02-11 2010-11-17 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011206A (zh) * 2011-12-22 2014-08-27 安斯泰来制药株式会社 新型抗人ctgf抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645525A (zh) * 2022-12-14 2023-01-31 北京大学第三医院（北京大学第三临床医学院） Ctgf中和抗体在制备防治绝经后骨关节炎的药物中的应用

Also Published As

Publication number Publication date
CA3142092A1 (en) 2020-12-10
MX2021014803A (es) 2022-01-18
BR112021023669A2 (pt) 2022-03-29
CN113840836B (zh) 2022-10-21
EP3981787A1 (en) 2022-04-13
TW202110880A (zh) 2021-03-16
CN115925926A (zh) 2023-04-07
WO2020244540A1 (zh) 2020-12-10
ZA202109744B (en) 2023-05-31
KR20220016890A (ko) 2022-02-10
US20220324953A1 (en) 2022-10-13
AU2020289303A1 (en) 2022-01-27
EP3981787A4 (en) 2022-09-14
JP2022535810A (ja) 2022-08-10

Similar Documents

Publication Publication Date Title
US11512129B2 (en) TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
US10899837B2 (en) B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
US20220220218A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
US20230138315A1 (en) Anti-angptl3 antibody and use thereof
CN112955473A (zh) 特异性结合vegf和ang2的双特异性抗体
CN113840836B (zh) 抗***生长因子抗体及其应用
WO2023078382A1 (zh) 结合gprc5d的抗体及其用途
CN116391041A (zh) 一种含抗***生长因子抗体的药物组合物
CN114057883A (zh) 双特异性抗原结合分子及其医药用途
WO2024088342A1 (en) Antibodies against cd24 and uses thereof
RU2807484C2 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и его фармацевтическое применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064840

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant